2
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Cardiovascular Risk Factors and Secondary Events Among Acute and Chronic Stable Myocardial Infarction Patients: Findings from a Managed Care Database

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Introduction

          Long-term risk for recurrent cardiovascular events among myocardial infarction (MI) patients in the acute versus chronic stable phase is not well characterized. This study was conducted to evaluate risk factors associated with all-cause mortality and cardiovascular (CVD) morbidity and to determine the transition period from the acute to chronic stable phase of disease.

          Methods

          Administrative claims data from a managed care database (2007–2012) were linked to the Social Security Death Index. Kaplan–Meier curves were generated over a 3-year period. The association between risk factors and clinical endpoints was assessed using Cox proportional hazard models. Poisson models estimated the ‘transition time’ from acute to chronic phase of disease.

          Results

          On average, recurrent cardiovascular event rates were higher among acute MI patients in comparison to the chronic MI patients during the first 3 months of follow-up. Over the 3-year follow-up period, survival curves became parallel and for some outcomes (i.e., acute myocardial infarction and bleeding events), were not statistically significantly different between the two groups. In both the acute and chronic MI cohorts, diabetes, heart failure, and renal disease were consistently statistically significant and positively associated with greater risk of death and ischemic events. PAD was consistently associated with increased risk among the chronic cohort and composite endpoints among the acute patients.

          Conclusions

          Greater understanding of differences in the CVD risk profiles and the transition from acute to chronic stable phase may help identify high-risk patients and inform clinical risk stratification and long-term disease management in MI patients.

          Funding

          Merck & Co., Inc., Kenilworth, NJ, USA.

          Electronic supplementary material

          The online version of this article (10.1007/s40119-019-00147-5) contains supplementary material, which is available to authorized users.

          Related collections

          Most cited references15

          • Record: found
          • Abstract: found
          • Article: not found

          Thrombin-receptor antagonist vorapaxar in acute coronary syndromes.

          Vorapaxar is a new oral protease-activated-receptor 1 (PAR-1) antagonist that inhibits thrombin-induced platelet activation. In this multinational, double-blind, randomized trial, we compared vorapaxar with placebo in 12,944 patients who had acute coronary syndromes without ST-segment elevation. The primary end point was a composite of death from cardiovascular causes, myocardial infarction, stroke, recurrent ischemia with rehospitalization, or urgent coronary revascularization. Follow-up in the trial was terminated early after a safety review. After a median follow-up of 502 days (interquartile range, 349 to 667), the primary end point occurred in 1031 of 6473 patients receiving vorapaxar versus 1102 of 6471 patients receiving placebo (Kaplan-Meier 2-year rate, 18.5% vs. 19.9%; hazard ratio, 0.92; 95% confidence interval [CI], 0.85 to 1.01; P=0.07). A composite of death from cardiovascular causes, myocardial infarction, or stroke occurred in 822 patients in the vorapaxar group versus 910 in the placebo group (14.7% and 16.4%, respectively; hazard ratio, 0.89; 95% CI, 0.81 to 0.98; P=0.02). Rates of moderate and severe bleeding were 7.2% in the vorapaxar group and 5.2% in the placebo group (hazard ratio, 1.35; 95% CI, 1.16 to 1.58; P<0.001). Intracranial hemorrhage rates were 1.1% and 0.2%, respectively (hazard ratio, 3.39; 95% CI, 1.78 to 6.45; P<0.001). Rates of nonhemorrhagic adverse events were similar in the two groups. In patients with acute coronary syndromes, the addition of vorapaxar to standard therapy did not significantly reduce the primary composite end point but significantly increased the risk of major bleeding, including intracranial hemorrhage. (Funded by Merck; TRACER ClinicalTrials.gov number, NCT00527943.).
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Atherothrombotic Risk Stratification and the Efficacy and Safety of Vorapaxar in Patients With Stable Ischemic Heart Disease and Previous Myocardial Infarction.

            Patients with stable ischemic heart disease and previous myocardial infarction (MI) vary in their risk for recurrent cardiovascular events. Atherothrombotic risk assessment may be useful to identify high-risk patients who have the greatest potential to benefit from more intensive secondary preventive therapy such as treatment with vorapaxar.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Early- and late-term clinical outcome and their predictors in patients with ST-segment elevation myocardial infarction and non-ST-segment elevation myocardial infarction.

              The disparity between ST-segment elevation myocardial infarction (STEMI) and non-STEMI (NSTEMI) remains controversial. We compared clinical outcomes and prognostic factors between STEMI and NSTEMI using large-scale registry data.
                Bookmark

                Author and article information

                Contributors
                lori_bash@merck.com
                Journal
                Cardiol Ther
                Cardiol Ther
                Cardiology and Therapy
                Springer Healthcare (Cheshire )
                2193-8261
                2193-6544
                20 August 2019
                20 August 2019
                December 2019
                : 8
                : 2
                : 329-343
                Affiliations
                [1 ]GRID grid.417993.1, ISNI 0000 0001 2260 0793, Merck & Co., Inc., ; Kenilworth, NJ USA
                [2 ]GRID grid.164295.d, ISNI 0000 0001 0941 7177, Department of Health Services Administration, , University of Maryland College Park School of Public Health, ; Maryland, USA
                [3 ]GRID grid.10698.36, ISNI 0000000122483208, Department of Emergency Medicine, School of Medicine, , University of North Carolina at Chapel Hill, ; Chapel Hill, NC USA
                [4 ]The Janssen Pharmaceutical Companies of Johnson & Johnson, Titusville, NJ USA
                [5 ]GRID grid.168010.e, ISNI 0000000419368956, Department of Medicine, Stanford Center for Clinical Research, , Stanford University School of Medicine, ; Stanford, CA USA
                Article
                147
                10.1007/s40119-019-00147-5
                6828898
                31432429
                4de868df-07de-44fe-945c-8de76340ee3c
                © The Author(s) 2019
                History
                : 31 May 2019
                Categories
                Original Research
                Custom metadata
                © The Author(s) 2019

                acute coronary syndrome,mortality,myocardial infarction,stable ischemic heart disease

                Comments

                Comment on this article